Non‐small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune‐related adverse events in first‐line treatments with immune checkpoint inhibitors: A retrospective single‐center study
Abstract Background Since 2015, immune checkpoint inhibitors have been a clinical treatment strategy for patients with advanced or recurrent non‐small cell lung cancer (NSCLC). However, the relationship between immune‐related adverse event (irAE) risk factors and patient clinical characteristics is...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-09-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14576 |